Trial Profile
A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g [EXTENSION OF: 700244200]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2014
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Acronyms TOPS
- Sponsors Genentech
- 10 May 2014 New trial record